UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002947
Receipt number R000002015
Scientific Title Evaluation of efficacy and safety of riboflavin/UVA treatment for keratoconus/keratectasia
Date of disclosure of the study information 2009/12/28
Last modified on 2017/07/04 19:43:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of efficacy and safety of riboflavin/UVA treatment for keratoconus/keratectasia

Acronym

efficacy and safety of riboflavin/UVA for keratoconus

Scientific Title

Evaluation of efficacy and safety of riboflavin/UVA treatment for keratoconus/keratectasia

Scientific Title:Acronym

efficacy and safety of riboflavin/UVA for keratoconus

Region

Japan


Condition

Condition

Keratoconus, keratectasia

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess efficacy and safety of riboflavin/UVA treatment on the cornea with keratoconus/keratectasia

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visual acuity, refraction, corneal curvature, corneal topography, corneal endothelial cell counts, and incidence of complications

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Collagen fibers of the corneal stroma will be crosslinked by the combination of instillation of riboflavin solution and ultraviolet-A irradiation for 30 minutes after corneal epithelial debridement.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

14 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Keratoconus or keratectasia
2. The most thinnest corneal thickness more than 400 micrometer
3. In cases with keratoconus, progression should be observed within recent 6 months. In cases with keratectasia, protrusion of the cornea should be progressed after the previous corneal refractive surgeries.

Key exclusion criteria

1. The corneal thickness less than 400 micrometer
2. Those who implanted medical instruments, such as pacemaker.
3. Ocular diseases, such as infection, corneal scar, herpetic keratitis, and/or nystagmus
4. Systemic diseases affecting corneal would healing
5. Eyes with narrow angle. Pregnant or breast-feeding women.
6. Occupation, by which refractive surgery is not arrowed

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuo Tsubota

Organization

Keio University School of Medicine

Division name

Department of Ophthalmology

Zip code


Address

Shinanomachi 35, Shinjuku-ku, Tokyo

TEL

03-3353-1211

Email

keio.eye.research.sec@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Naoko Kato

Organization

Keio University School of Medicine

Division name

Department of Ophthalmology, Refractive Surgery Clinic

Zip code


Address

Shinanomachi 35, Shinjuku-ku, Tokyo

TEL

03-3353-1211

Homepage URL


Email

nkato@ndmc.ac.jp


Sponsor or person

Institute

Department of Ophthalmology, Keio University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 12 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 11 Month 19 Day

Date of IRB


Anticipated trial start date

2009 Year 02 Month 01 Day

Last follow-up date

2017 Year 01 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 12 Month 28 Day

Last modified on

2017 Year 07 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002015


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name